Multiple sclerosis by the numbers

1M+ Number of people in the United States living with multiple sclerosis
3x Women are three times more likely than men to have multiple sclerosis
20-50 Age of people most likely to be diagnosed with multiple sclerosis

 

Multiple sclerosis (MS) is a neurological disease that affects approximately 1 million people in the U.S. Since symptoms vary widely among patients and may overlap with other neurological conditions, providers rely on rule-out testing before arriving at a diagnosis, causing challenges in early evaluation.

Labcorp’s comprehensive MS portfolio gives you the insights needed to rule out other conditions, while providing diagnostic, prognostic and monitoring solutions that can improve health and outcomes for MS patients.  

Diagnosing MS through blood-based testing  

There is no single test to diagnose MS, so having a trusted laboratory partner that provides supportive testing is essential. Labcorp offers a comprehensive portfolio of testing options that help to streamline ordering and lessen the patient burden.   
 


MS patient management and monitoring 

Understanding a patient’s MS journey is crucial to personalizing care and identifying the right treatment. New blood biomarkers—neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP)—provide valuable insight into disease activity and progression between MRIs, minimizing patient burden and helping you evaluate and monitor MS with greater clarity.  

As the only national reference lab to offer NfL and GFAP testing, Labcorp is proud to offer a suite of blood-based biomarker tests for MS that empower you to make informed treatment decisions tailored to each patient's specific disease stage. 
 

Disease Monitoring

Number Name

Labcorp also offers Stratify JCV™ Ab w/Index (819372) as a send-out test.

Clinical utility of biomarkers in MS  

Though NfL has proven to be an effective marker to gauge therapeutic response in active disease—and has now been included in the Consortium of Multiple Sclerosis Centers guidelines for this use, among others1—GFAP has demonstrated stronger prediction of disease progression, irrespective of relapse activity.2,3 Additionally, serial GFAP measurements can be a marker of disease severity.3,4 Together, NfL and GFAP are new ways of helping physicians evaluate and monitor MS patients with simple blood draws that not only complement MRI, but may also reduce the needed frequency of MRI.  
 

Gaining clarity with cutting-edge diagnostics 

As new therapies emerge for MS treatment and management, having the right lab partner is essential to improving patient outcomes. We are committed to helping you transform MS care, which is why we continue to expand our MS portfolio to equip you with the latest diagnostic tools and emerging biomarkers.  

When you need guidance on vague symptoms and disease progression for MS, our extensive testing options provide clear answers. Contact us to learn more about our MS portfolio or explore our offerings for other neurological and autoimmune disorders.  
 

Labcorp can help meet your needs for MS testing

Explore More Neurodegenerative Capabilities

ALS, Ataxias, & Huntington's

Genetics can play a significant role in the development of certain neurodegenerative diseases. In some cases, genetic testing may help confirm a diagnosis.

Alzheimer's

Finding a way to diagnose Alzheimer's earlier and easier is a key goal for Labcorp.

Muscular Dystrophy

Characterized by progressive muscle loss and weakness, our tests can detect the genetic mutations that cause the most common forms.

Biomarkers for Drug Development

The increasing prevalence of neurodegenerative diseases has fueled the need for advanced research into pharmaceutical solutions and related neuro biomarkers.

References

  1. Consortium of Multiple Sclerosis Centers Neurofilament Consensus Panel. CMSC best practices for the use of serum neurofilament (sNFL) in MS Management.” January 10, 2024. https://www.mscare.org/page/NFL 
  2. Meier S, Willemse EA, Schaedelin S, et al. Serum glial fibrillary acidic protein compared with neurofilament light chain as a biomarker for disease progression in multiple sclerosis. JAMA Neurol. 2023;80(3):287-297. doi:10.1001/jamaneurol.2022.5250 
  3. Abdelhak A, Hottenrott T, Morenas-Rodríguez E et al. Glial activation markers in CSF and serum from patients with primary progressive multiple sclerosis: potential of serum GFAP as disease severity marker? Front Neurol. 2019;10:280. doi:10.3389/fneur.2019.00280 
  4. Abdelhak A, Huss A, Kassubek J, Tumani H, Otto M. Serum GFAP as a biomarker for disease severity in multiple sclerosis. Sci Rep. 2018;8(1):14798. doi:10.1038/s41598-018-33158-8